Dr Ian Vela awarded the 2015 TOLMAR ANZUP Uro-Oncology Clinical Research Fellowship
“This project builds on world first technology developed in association with the Hubrecht Institute in the Netherlands during my Urologic Oncology Fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC),” explains Dr Vela.
“With the aid of this award, I intend to establish locally this novel technology, and integrate it into clinical trial workflow and as part of a potential precision medicine program.”
Presentation of the fellowship, which is valued at $60,000, was made at the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group Annual Scientific Meeting in Sydney on 14 July 2015.
The CRF is offered annually to clinician scientists whose research aligns with ANZUP’s mission to conduct clinical trial research to improve treatment of bladder, kidney, testicular and prostate cancers. This year the focus was on prostate cancer research.
ANZUP Cancer Trials Group is an active and emerging cooperative trials group, established to bring together all the professional disciplines and groups involved in researching and treating urogenital cancers, and committed to supporting and encouraging members to actively participate in clinical trials research.
TOLMAR Australia is a specialist uro-oncology company providing medicines and locally informed support to men with advanced prostate cancer, as well as healthcare professionals in Australia and New Zealand.
